Milrinone Tillomed (Milrinone)

• Milrinone is used in the management of acute cardiac conditions that involve reduced contractility and low cardiac output.
• Acute decompensated heart failure: improves cardiac output and reduces pulmonary congestion.
• Cardiogenic shock: provides inotropic support to maintain systemic perfusion.
• Post‑cardiac surgery low‑output syndrome: enhances myocardial performance to facilitate weaning from mechanical support.

• Milrinone selectively inhibits phosphodiesterase‑3 enzymes in cardiac and vascular smooth muscle cells, leading to an accumulation of intracellular cyclic adenosine monophosphate (cAMP). Elevated cAMP enhances calcium influx during systole, increasing myocardial contractility, while also promoting vasodilation of systemic and pulmonary vessels, thereby reducing afterload and improving cardiac output.

Milrinone may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Hypotension: reduction in systemic blood pressure.
• Tachyarrhythmias: premature ventricular or atrial beats.
• Headache: mild to moderate intensity.
• Nausea: occasional gastrointestinal upset.
• Flushing: transient warmth and reddening of skin.
• Palpitations: awareness of rapid heartbeats.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure requiring intervention.
• Ventricular tachycardia or fibrillation: life‑threatening rhythm disturbances.
• Myocardial ischemia: chest pain due to reduced coronary perfusion.
• Anaphylactic reaction: rare allergic response with rash, swelling, or airway compromise.
• Thrombocytopenia: significant drop in platelet count.
• Hepatic dysfunction: abnormal liver enzyme elevations.

• Milrinone requires careful monitoring and specific safety measures before and during therapy.
• Monitor blood pressure: watch for hypotension and adjust infusion rate.
• Observe cardiac rhythm: continuous ECG monitoring for arrhythmias.
• Assess renal function: dose may need adjustment in renal impairment.
• Use cautiously in recent myocardial infarction: risk of ischemia.
• Avoid in severe aortic stenosis: may precipitate hemodynamic collapse.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Milrinone can interact with several medications, influencing its efficacy and safety profile.

Major Interactions (Avoid)

• Other phosphodiesterase‑3 inhibitors: additive inotropic and vasodilatory effects.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase plasma concentrations.
• Concurrent vasodilators (e.g., nitroglycerin): risk of profound hypotension.
• Digoxin: heightened risk of arrhythmias.
• Beta‑blockers: may blunt desired inotropic response.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inducers (e.g., rifampin): may reduce effectiveness.
• Loop diuretics: synergistic effect on electrolyte balance.
• Anticoagulants: monitor for bleeding if thrombocytopenia occurs.
• Calcium channel blockers: potential additive vasodilation.
• NSAIDs: may affect renal clearance of Milrinone.